Project Details
Description
Although ERT with elosulfase alfa is a therapeutic option for mucopolysaccharidosis IVA (MPS IVA) patients, it has limited impact on the bone, immunological issues, and a high cost. In this sense, it is necessary to identify new treatment alternatives for these patients or to improve the therapeutic efficacy of ERT.
Status | Finished |
---|---|
Effective start/end date | 01/01/21 → 31/07/23 |
Project funding
- International
- NATIONAL MPS SOCIETY